Table of Contents

2024-9-12

Autoimmune bullous diseases induced by cyclin-dependent kinase 4/6 inhibitors—first cohort from the EADV Task Force ‘Dermatology for Cancer Patients’

2024-9-12

Editorial Board

2024-9-12

Optimizing Rectal Cancer Treatment: A Path Towards Personalization

2024-9-12

603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation

2024-9-1

587P Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): Results from the comprehensive genomic profiling (CGP) trial FPG500

2024-9-1

1977P Efficacy of talazoparib and avelumab as a maintenance treatment in patients with advanced/metastatic urothelial carcinoma (mUC) whose disease did not progress after a first-line platinum-based chemotherapy (PBCT): The GETUG-TALASUR trial

2024-9-1

832P CLOMB: A validated scoring model to predict the relapse in the central nervous system of pediatric acute B-cell lymphoblastic leukemia

2024-9-1

634P First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors

2024-9-1

1495P Impact of social isolation on the clinical outcomes in advanced NSCLC patients

2024-9-1

470P Mitochondrial ribosomal proteins (MRPs) in glioblastoma multiforme: Omics approach

2024-9-1

1403P A phase II study of tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: Long-term follow-up outcomes of TD-NICE

2024-9-1

830P Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene

2024-9-1

1422P First-line rilvegostomig (rilve) + chemotherapy (CTx) in patients (pts) with HER2-negative (HER2–) locally advanced unresectable or metastatic gastric cancers: First report of GEMINI-Gastric sub study 2

2024-9-1

221P ANGPTL4's role in cancer: A meta analysis and bioinformatics exploration

2024-9-1

998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study

2024-9-1

438TiP Trastuzumab deruxtecan with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: An exploratory, multi-center, single-arm, phase II study (TROPHY, trial in progress)

2024-9-1

1051P Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitors

2024-9-1

83P Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in eary high risk breast cancer: The CITUCEL trial update

2024-9-1

1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial

2024-9-1

LBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

2024-9-1

Subcutaneous versus intravenous nivolumab for renal cell carcinoma

2024-9-1

187P Organoid growth-based oncological sensitivity test (OncoSensi) for predicting radiation therapy outcomes in pharyngeal and esophageal cancer

2024-9-1

186P Differences in antigen and immune marker expression in lymphoepithelioma-like carcinoma (LELC) and nasopharyngeal carcinoma (NPC): A multiplex immunohistochemistry (mIHC), spatial transcriptomic and multiplex immunofluorescence (mIF)-based analysis

2024-9-1

987TiP First-in-human dose escalation trial of fourth generation chimeric antigen receptor (CAR) T cell therapy (EU307) in patients with glypican-3 (GPC3) positive hepatocellular carcinoma (HCC)

2024-9-1

825P Ultra-sensitive cfDNA analysis for minimally invasive measurable residual disease detection and profiling in multiple myeloma

2024-9-1

641P Phase I/II clinical and pharmacokinetic study of ecubectedin in combination with irinotecan in patients with selected advanced solid tumors

2024-9-1

1554P Co payments in cancer patients: Analysis and estimating OOP

2024-9-1

1615P A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)

2024-9-1

1512P The role of pancreaticoduodenectomy for octogenarians with pancreatic cancer

2024-9-1

1447P Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

2024-9-1

861P Neo-TIME trial: Neoadjuvant tislelizumab combined with albumin-paclitaxel, cisplatin, and fluorouracil(APF) in patients with locally advanced oral squamous cell carcinoma (LA-OSCC)

2024-9-1

1060P Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: A metrology informatics analysis based on machine learning

2024-9-1

379P Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic breast cancer: A multicentre international retrospective cohort study

2024-9-1

260P Impact of HER2-low status on clinicopathological characteristics and pathological complete response in luminal and triple-negative early breast cancer

2024-9-1

54P BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic biliary tract carcinoma (BTC)

2024-9-1

LBA38 Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, phase II/III study (DUBHE-H-308)

2024-9-1

LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients

2024-9-1

LBA68 Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial

2024-9-1

1980P Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial

2024-9-1

1942O Application of GigaPath: An open-weight billion-parameter AI foundation model based on a novel vision transformer architecture for cancer mutation prediction and TME analysis

2024-9-1

1347P Efficacy and safety of immune checkpoint inhibitor rechallenge in advanced lung cancer: A multicenter, real-world study

2024-9-1

1342P The efficacy of pembrolizumab vs nivolumab plus ipilimumab in metastatic NSCLC in relation to PD-L1 and TMB status

2024-9-1

171P A computational pathology collagen signature predictive of tamoxifen benefit in ductal carcinoma in situ: Results from a cohort within the UK/ANZ DCIS randomized trial

2024-9-1

169P Analysis of tumor immune microenvironment with mIHC in Chinese non-small cell lung cancer

2024-9-1

798TiP Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy: SOPRANO trial

2024-9-1

2017P Intrinsic molecular difference between bladder and upper tract urothelial carcinomas and its impacts in treatment response

2024-9-1

146P Biomarkers and intrinsic/acquired resistance mechanisms for atezolizumab plus chemoradiotherapy in MSS locally advanced rectal cancer: An exploratory analysis of a single center, phase II study

2024-9-1

1170P Convergent and divergent determinants of heterogeneity, biomarkers, and plasticity in thoracic and prostate neuroendocrine tumors

2024-9-1

722P Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial

2024-9-1